IMM: Major clinical progress, strong finances, and all resolutions passed amid sector challenges

Quartr

The meeting highlighted strong financial management, major clinical milestones in oncology and autoimmune programs, and robust strategic partnerships. All resolutions were passed without opposition, and leadership changes were announced. Key risks include regulatory and supply chain challenges.

Based on Immutep Ltd [IMM] AGM 2025 Audio Transcript — Nov. 27 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

IMM: Strong financials, clinical progress, and key resolutions mark a pivotal year of growth

Quartr

Immutep

+5.20%

The meeting highlighted strong financial management, major clinical progress in oncology and autoimmune programs, and robust governance. Key resolutions were passed, and the company remains well-funded and focused on advancing its global phase III trial and pipeline milestones.

Based on Immutep Ltd [IMM] AGM 2025 Audio Transcript — Nov. 27 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IMM: Strong cash position, clinical progress, and S&P/ASX 300 inclusion drive future growth

Quartr

Immutep

+5.20%

The meeting reviewed strong financials with a cash runway to end of CY2026, highlighted progress in clinical trials for efti and IMP761, and discussed strategic collaborations and IP strength. Addition to the S&P/ASX 300 and positive KOL feedback were noted.

Original document: Immutep Ltd [IMM] Slides Release — Nov. 27 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IMM: Global phase III lung cancer trial on track, with major data and partnership catalysts ahead

Quartr

Immutep

+5.20%

Eftilagimod alpha is advancing in a global phase III lung cancer trial, with a key futility analysis due in Q1 and final readouts expected by 2026–2027. The pipeline includes promising results in soft tissue sarcoma and early-stage autoimmune programs, supported by strong financials and ongoing partnerships.

Based on Immutep Ltd [IMM] Bell Potter Healthcare Conference 2025 Audio Transcript — Nov. 19 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IMM: Global phase three lung cancer trial nears key futility analysis, with multiple pipeline updates ahead

Quartr

Immutep

+5.20%

Eftilagimod alpha is advancing in a global phase three lung cancer trial, with strong prior efficacy and safety data and a major futility analysis due in Q1 next year. Additional programs in sarcoma and autoimmune diseases are progressing, supported by robust financials and key partnerships.

Based on Immutep Ltd [IMM] Bell Potter Healthcare Conference 2025 Audio Transcript — Nov. 19 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

IMM: Clinical trials progress and robust cash position extend funding runway to end of CY2026

Quartr

Immutep

+5.20%

Pivotal clinical trials in oncology advanced, with strong cash reserves of A$109.85 million supporting a funding runway to end of CY2026. Positive regulatory feedback and new patents bolster future prospects, while R&D spending remains the primary cash outflow.

Original document: Immutep Ltd [IMM] Earnings Release — Oct. 28 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

Immutep Target Price Cut 34% to A$0.46/Share by Bell Potter>IMM.AU

Dow Jones Newswires

Immutep

+5.20%

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

IMM: Major clinical progress, strong finances, and all resolutions passed amid sector challenges

IMM: Strong financials, clinical progress, and key resolutions mark a pivotal year of growth

IMM: Strong cash position, clinical progress, and S&P/ASX 300 inclusion drive future growth

IMM: Global phase III lung cancer trial on track, with major data and partnership catalysts ahead

IMM: Global phase three lung cancer trial nears key futility analysis, with multiple pipeline updates ahead

IMM: Clinical trials progress and robust cash position extend funding runway to end of CY2026

Immutep Target Price Cut 34% to A$0.46/Share by Bell Potter>IMM.AU

Risk Disclosure